GeNeuro SA (FRA:GEM)

Germany flag Germany · Delayed Price · Currency is EUR
0.0362
+0.0012 (3.43%)
At close: Nov 28, 2025
-61.89%
Market Cap1.26M
Revenue (ttm)n/a
Net Income (ttm)-14.76M
Shares Outn/a
EPS (ttm)-0.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume1,843
Open0.0362
Previous Close0.0350
Day's Range0.0362 - 0.0362
52-Week Range0.0200 - 0.6300
Betan/a
RSI54.43
Earnings DateFeb 6, 2026

About GeNeuro

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development progra... [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 17
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol GEM
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.